Traduction de «food product that contains » (Néerlandais → Français) :

De termen en voorwaarden opgenomen in het register op de website van de Europese Commissie vermelden “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.
Les termes et conditions repris sur le registre du site de la Commission européenne mentionnent que “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.

Each 250 ml bottle of this product contains the following ingredients (the following list is restricted to the ingredients that can cause problems in terms of food safety): 80 mg caffeine (or 320 mg/litre), 1 000 mg taurine (4 000 mg/litre), 600 mg glucuronolactone (2 400 mg/litre), 5 µg vitamin B12, 5 µg vitamin B6, 5 mg vitamin B5, 1.5 mg vitamin B2 and 20.5 mg vitamin B3.
Celle-ci contient, par flacon de 250 ml, les composants suivants (liste limitée aux substances pouvant poser problème en termes de sécurité alimentaire): 80 mg de caféine (soit 320 mg/litre), 1.000 mg de taurine (4.000 mg/litre), 600 mg de D-glucuronolactone (2.400 mg/litre), 5 µg de vitamine B12, 5 mg de vitamine B6, 5 mg de vitamine B5, 1,5 mg de vitamine B2 et 20,5 mg de vitamine B3.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

A European regulation that has entered into force on 1 July 2004 stipulates that, in order to inform the consumer of possible health risks, the labelling of beverages that contain caffeine in a proportion in excess of 150 mg/l should contain the mention “high caffeine content” followed by the caffeine content expressed in mg/100 ml in the same field of vision as the name under which the product is sold (Directive 2002/67/EC).
Enfin, une réglementation européenne, entrée en vigueur au 1er juillet 2004, stipule que l’étiquetage de boissons contenant plus de 150 mg de caféine par litre doit comporter la mention « teneur élevée en caféine » et la mention de sa quantité (en mg/100 ml) dans le même champ de vision du produit afin d’avertir le consommateur des risques possibles pour la santé (Directive 2002/67/CE).

As for D-glucuronolactone, the group believes that this concerns a normal human metabolite deriving from glucose, which does not involve a structural risk with regard to mutagenicity or carcinogenicity. It also holds that both this component as well as its hydrolysis product, glucuronic acid, are endogenous metabolites in humans and other mammals, that they are naturally present in various food sources and that they are quickly metabolised into innocuous products and excreted.
Pour la D-glucuronolactone, le groupe considère qu’il s’agit d’un métabolite humain normal provenant du glucose qui ne présente pas de risque structural en termes de mutagénicité ou de carcinogénicité, que pour ce composant, comme pour son produit d’hydrolyse, l’acide glucuronique, il s’agit de métabolites endogènes chez l’homme et les autres mammifères, qu’ils se trouvent à l’état naturel dans diverses sources alimentaires et qu’ils sont rapidement métabolisés en produits sans danger et excrétés.

The objective of this consultation platform is to determine an indicative status for products that lie on the boundaries between medicines, medical devices, foods or food supplements, cosmetics or biocides.
The objective of this consultation platform is to determine an indicative status for products that lie on the boundaries between medicines, medical devices, foods or food supplements, cosmetics or biocides.

In de 'Code of Practice for the reduction of 3-monochloropropane-1,2-diol (3-MCPD) during the production of acid-hydrolysed vegetable proteins (acid-HVPs) and products that contain acid-HVPs' (in het Engels, Codex Alimentarius, CAC/RCP 64-2008) kunt u preventie- en reductiestrategieën vinden.
Vous trouverez des stratégies de prévention et de réduction dans le « Code d’usages pour la réduction des teneurs en 3-Monochloropropane-1,2diol (3-MCPD) lors de la production de Protéines Végétales Hydrolysées obtenues par voie Acide (PVHA) et de produits contenant ce type de protéines » (Codex Alimentarius, CAC/RCP 64-2008).

As regards D- glucuronolactone, the SCF confirms its reservations about a daily chronic intake of 840 mg of the product (1.4 can) and an acute intake of 1 800 mg of the product (3 cans) via this type of drink, taking into account that the natural intake of D-glucuronolactone via food amounts to 1 to 2 mg/day (SCF, 2003).
Pour le D-glucuronolactone, le SCF confirme ses réserves dans le cadre d’un apport journalier chronique de 840 mg de produit (1,4 canette) et d’un apport aigu de 1.800 mg de produit (3 cannettes) via ce type de boisson et ce, tenant compte du fait que l’apport alimentaire naturel en D-glucuronolactone est de 1 à 2 mg/jour (SCF, 2003).

The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.
The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.